Catalog No.
RHC90101
Species reactivity
Human
Host species
Rabbit
Isotype
IgG
Clonality
Monoclonal
Applications
FCM, IF, WB
Recommended Dilution
| Application |
Dilution |
| FCM |
1:20-1:100, IF: 1:50-1:200, WB: 1:1000-1:2000 |
Target
CYP2C9, Cytochrome P450 PB-1, Cytochrome P450 MP-8, (S)-limonene 7-monooxygenase, CYP2C10, (S)-limonene 6-monooxygenase, (R)-limonene 6-monooxygenase, S-mephenytoin 4-hydroxylase, Cholesterol 25-hydroxylase, Cytochrome P450 2C9, Cytochrome P450 MP-4, CYPIIC9, Cytochrome P-450MP
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P11712
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% BSA, 50% Glycerol, 0.05% Sodium azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 4 ℃ for frequent use. Store at -20 ℃ for twelve months from the date of receipt.
Clone ID
R1N45
Note
For research use only.
Metabolism of sesamin by cytochrome P450 in human liver microsomes., PMID:20851877
Bullous allergic drug eruption with presence of myeloperoxidase and reorganization of the dermal vessels observed by using CD34 and collagen IV antibodies., PMID:22540071
Increased warfarin consumption and residual fibrin turnover in thrombotic patients with primary antiphospholipid syndrome., PMID:21371740
The ligands of estrogen receptor α regulate cytochrome P4502C9 (CYP2C9) expression., PMID:21493749
In vitro characterization of the cytochrome P450 isoforms involved in the metabolism of 6-methoxy-2-napthylacetic acid, an active metabolite of the prodrug nabumetone., PMID:21532165
Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes., PMID:21704641
Immunochemical detection of cytochrome P450 enzymes in liver microsomes of 27 cynomolgus monkeys., PMID:21849623
Inhibition of cytochrome P450 enzymes involved in ketamine metabolism by use of liver microsomes and specific cytochrome P450 enzymes from horses, dogs, and humans., PMID:22023129
Interleukin-6 and cytochrome-P450, reason for concern?, PMID:22451032
Genome-wide association study of antibody response to smallpox vaccine., PMID:22542470
Serum-free culture of primary human hepatocytes in a miniaturized hollow-fibre membrane bioreactor for pharmacological in vitro studies., PMID:23165723
Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure., PMID:23775837
In vitro identification of cytochrome P450 enzymes responsible for drug metabolism., PMID:23824861
In vitro metabolism of a novel antithrombotic compound, S002-333, and its enantiomers: quantitative cytochrome P450 phenotyping, metabolic profiling and enzyme kinetic studies., PMID:23992115
Isoniazid hepatotoxicity: progress in understanding the immunologic component., PMID:24037911
Expression of selected cytochrome P450 isoforms and of cooperating enzymes in colorectal tissues in selected pathological conditions., PMID:24485758
Immunochemical detection of cytochrome P450 enzymes in small intestine microsomes of male and female untreated juvenile cynomolgus monkeys., PMID:24593267
The development of humanized liver with Rag1 knockout rats., PMID:24815157
Immunochemical quantification of cynomolgus CYP2J2, CYP4A and CYP4F enzymes in liver and small intestine., PMID:25138712
Differential expression of cytochrome P450 enzymes from the CYP2C subfamily in the human brain., PMID:25504503
Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach., PMID:26054042
Dietary Doses of Sulforaphane Affect Hepatic Drug Metabolizing Enzymes in Spontaneously Hypertensive Rats., PMID:26084424
Novel Marmoset Cytochrome P450 2C19 in Livers Efficiently Metabolizes Human P450 2C9 and 2C19 Substrates, S-Warfarin, Tolbutamide, Flurbiprofen, and Omeprazole., PMID:26228688
CYP450 Enzyme-Mediated Metabolism of TCAS and Its Inhibitory and Induced Effects on Metabolized Enzymes in Vitro., PMID:26404338
Physiologically Based Pharmacokinetic Model to Assess the Influence of Blinatumomab-Mediated Cytokine Elevations on Cytochrome P450 Enzyme Activity., PMID:26451330
Cyclophosphamide treatment-induced leukopenia rates in ANCA-associated vasculitis are influenced by variant CYP450 2C9 genotypes., PMID:26894931
Development of a Physiologically Based Pharmacokinetic Model to Predict Disease-Mediated Therapeutic Protein-Drug Interactions: Modulation of Multiple Cytochrome P450 Enzymes by Interleukin-6., PMID:26961818
Therapeutic protein-drug interaction assessment for daclizumab high-yield process in patients with multiple sclerosis using a cocktail approach., PMID:26991517
Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol., PMID:27836712
Metabolic characterization of (1-(5-fluoropentyl)-1H-indol-3-yl)(4-methyl-1-naphthalenyl)-methanone (MAM-2201) using human liver microsomes and cDNA-overexpressed cytochrome P450 enzymes., PMID:27924364
Correlations of CYP2C9*3/CYP2D6*10/CYP3A5*3 gene polymorphisms with efficacy of etanercept treatment for patients with ankylosing spondylitis: A case-control study., PMID:28248857
Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228)., PMID:28817838
The Inhibitory Effect of Telmisartan on the Metabolism of Arachidonic Acid by CYP2C9 and CYP2C8: An in Vitro Study., PMID:28867723
Evaluation of Potential Disease-Mediated Drug-Drug Interaction in Patients With Moderate-to-Severe Atopic Dermatitis Receiving Dupilumab., PMID:29498038
CYP2J2 is the major enzyme in human liver microsomes responsible for hydroxylation of SYL-927, a novel and selective sphingosine 1-phosphate receptor 1 (S1P1 ) agonist., PMID:30362120
Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis., PMID:30574672
Prosthetic valve thrombosis - association of genetic polymorphisms of VKORC1, CYP2C9 and CYP4F2 genes., PMID:30732170
Effect of Dietary Doses of Quercetin on Hepatic Drug Metabolizing Enzymes in Spontaneously Hypertensive Rats., PMID:31065969
Steroid hormone-related polymorphisms associate with the development of bone erosions in rheumatoid arthritis and help to predict disease progression: Results from the REPAIR consortium., PMID:31616008
Mertansine Inhibits mRNA Expression and Enzyme Activities of Cytochrome P450s and Uridine 5'-Diphospho-Glucuronosyltransferases in Human Hepatocytes and Liver Microsomes., PMID:32131538
Evaluating Potential Disease-Mediated Protein-Drug Interactions in Patients With Moderate-to-Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab., PMID:32407591
Modulation of CYP2C9 activity and hydrogen peroxide production by cytochrome b5., PMID:32968106
Spontaneous Spinal Epidural Hematoma During Simultaneous Tocilizumab and Warfarin Use in a Patient With Rheumatoid Arthritis: Is There a Drug Interaction Between Tocilizumab and Oral Anticoagulants?, PMID:33758819
Targeted Metabolomics Study of Human Plasma Revealed Activation of the Cytochrome P450 Epoxygenase/Epoxide Hydrolase Axis in Patients with IgA Nephropathy., PMID:36301320
Evaluation of the potential impact on pharmacokinetics of various cytochrome P450 substrates of increasing IL-6 levels following administration of the T-cell bispecific engager glofitamab., PMID:38044486
An in silico investigation of the toxicological effects and biological activities of 3-phenoxybenzoic acid and its metabolite products., PMID:38833509
Inflammation-mediated drug interactions of olokizumab and cytochrome P450 activities in patients with rheumatoid arthritis., PMID:38984761
[Siponimod (BAF312): General Characteristics and Clinical Implications of Pharmacogenomic Dosage in the Treatment of Active Secondary Progressive Multiple Sclerosis]., PMID:39093141
Evaluation of Drug-Drug Interaction Potential of Talquetamab, a T-Cell-Redirecting GPRC5D × CD3 Bispecific Antibody, as a Result of Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma in MonumenTAL-1, Using a Physiologically Based Pharmacokinetic Model., PMID:39285155
Evaluation of the Effect of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease., PMID:39707077
For research use only. Not for human or drug use.
